A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab and Best Supportive Care Versus Placebo and Best Supportive Care as Second-Line Treatment in Patients with Hepatocellular Carcinoma Following First-Line Therapy with Sorafenib
ID Number 11-1738Principal Investigator(s)
Department(s) or Division(s)
The purpose of this study is to look at the effects of the experimental drug Ramucirumab Drug Product (DP) with best supportive care (following disease progression on first line sorafenib therapy) in patients with hepatocellular carcinoma. Ramucirumab potentially blocks the vascular endothelial growth factor receptor 2 (VEGFR2). VEGFR2 is a protein thought to be important in the growth of hepatocellular cancer. The study will also look at what side effects you may have and how you feel when you are receiving treatment. It will test how long Ramucirumab Drug Product (DP) remains in your blood and how your body gets rid of the drug. This study will also investigate the growth or spread of your cancer by measuring the size of your tumor(s) to see if they have decreased in size or increased in size or disappeared.
You may qualify to take part in this research study because you have been diagnosed with advanced hepatocellular carcinoma, a type of liver cancer, and it has progressed.
Recruiting Patients: Yes